Global Pars Planitis Treatment Market, By Treatment (Corticosteroid, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Surgery, Cryotherapy, Immunomodulatory Therapy, Others), Diagnosis (Blood Tests, X-ray, Magnetic Resonance Imaging (MRI), Others), Symptoms (Blurred Vision, Dark Floaters in the Visual Field, Swelling Inside the Eye, Vision Loss, Glaucoma, Cataracts, Retinal Detachment, Others), Dosage (Injection, Tablets, Eye Drops, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
Pars Planitis Treatment Market Analysis and Size
The increase in pars planitis will act as a primary driver that will result in the expansion of market growth. Although pars planitis is usually benign, there can be major vision loss in severe cases. Pars planitis mainly affects children and adolescents. Even though it is uncommon for patients to become blind from pars planitis, as many as 20% can suffer visual loss if the condition goes untreated.
Data Bridge Market Research analyses that the pars planitis treatment market, which was USD 595.11 billion in 2022, would rise to USD 999.8 billion by 2030, and is expected to undergo a CAGR of 6.70% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Pars Planitis Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Corticosteroid, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Surgery, Cryotherapy, Immunomodulatory Therapy, Others), Diagnosis (Blood Tests, X-ray, Magnetic Resonance Imaging (MRI), Others), Symptoms (Blurred Vision, Dark Floaters in the Visual Field, Swelling Inside the Eye, Vision Loss, Glaucoma, Cataracts, Retinal Detachment, Others), Dosage (Injection, Tablets, Eye Drops, Others), Route of Administration (Oral, Intravenous, Others), End-Users (Clinic, Hospital, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Quantum Cryogenics (U.K.), BTG International Inc. (U.S.), CryoConcepts LP (U.S.)., Zimmer MedizinSysteme GmbH (Germany), Medtronic (Ireland), Cortex Technology (Denmark), CooperSurgical, Inc. (U.S.), AtriCure, Inc (U.S.)., Hologic, Inc. (U.S)., Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), AbbVie Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India)., Aurobindo Pharma (India), and AstraZeneca (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Pars planitis is when the eye's uvea, or center layer, becomes inflamed. In this condition, the restricted area (pars plana) between the colored section of the eye, called the iris, and the choroid becomes swelled. This can cause black, blurred vision, floating areas in the eyesight, and vision loss over time. Cataracts, macular edema, and retinal detachment may develop as the condition progresses.
Global Pars Planitis Treatment Market Dynamics
Drivers
- Increasing Prevalence of Pars Planitis
The increasing incidence of pars planitis leads to the market's growth during the forecast period. Most cases of intermediate uveitis in children exist without an underlying disease. Its annual incidence has been reported to be 1.4 - 2 cases per 100,000 population in France and the United States (U.S.). Furthermore, in a retrospective study, Ozdal et al. witnessed pars planitis as the top cause of pediatric uveitis, with a rate of 24%. Thus, this increasing incidence of pars planitis leads to a higher demand for its treatment processes. This factor leads to the growth of the market.
- Increasing Treatment Variations in Pars Palnitis
There are increasing treatment options for pars planitis that lead to market growth. Treatment options include periocular corticosteroid (CS) injections followed by oral prednisone if considered ineffective, cryotherapy or laser photocoagulation, pars plana vitrectomy, and immunosuppressive treatment the market growth. Periocular CS injections are advantageous, mainly in unilateral or asymmetrical involvement patients and macular edema. Thus, this factor help in the market growth.
Opportunities
- Varied Availability of Diagnostic Procedures
There are varied diagnostic methods associated with this treatment that lead to the market's growth. The current four-step therapy consists of immunosuppressives, corticosteroids, anti-TNF-α agents, and pars plana vitrectomy or laser photocoagulation for managing complications. Few patients have severe disease in both eyes, and the best option is an oral agent that reduces the immune system. Therefore, this factor acts as a major factor that increases market growth.
Restraints/Challenges
- High Cost of Pars Planitis Treatment Methods
Various treatment processes are of high cost, which further impedes the market growth. Treatment methods such as cryotherapy or laser photocoagulation, and pars plana vitrectomy are very costly. They cannot be afforded by most of the hospitals in the underdeveloped and developing countries which starts affecting the patient's health. Thus, this factor impedes market growth.
This pars planitis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pars planitis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Pars Planitis Treatment Market Scope
The pars planitis treatment market is segmented on the basis of treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Corticosteroid
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Surgery
- Cryotherapy
- Immunomodulatory Therapy
- Others
Diagnosis
- Blood Tests
- X-ray
- Magnetic Resonance Imaging (MRI)
- Others
Symptoms
- Blurred Vision
- Dark Floaters in the Visual Field
- Swelling Inside the Eye
- Vision Loss
- Glaucoma, Cataracts
- Retinal Detachment
- Others
Dosage
- Injection
- Tablets
- Eye Drops
- Others
Route of Administration
- Oral
- Intravenous
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
End User
- Clinic
- Hospital
- Others
Pars Planitis Treatment Market Regional Analysis/Insights
The pars planitis treatment market is analyzed and market size insights and trends are provided by treatment, diagnosis, symptoms, dosage, route of administration, end-users and distribution channel and end user as referenced above.
The countries covered in the pars planitis treatment market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific is expected to grow during the pars planitis treatment market forecast because of the growing patient pool and rising investment in the healthcare sector. Also, increasing government support associated with its treatment and diagnostic procedures leads to market growth.
North America dominates the market in the forecast period due to the presence of major market players and high disposable income. Also, the well-developed healthcare infrastructure in this region will lead to market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The pars planitis treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for pars planitis treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the pars planitis treatment market. The data is available for historic period 2011-2021.
Competitive Landscape and Pars Planitis Treatment Market Share Analysis
The pars planitis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pars planitis treatment market.
Some of the major players operating in the pars planitis treatment market are:
- Quantum Cryogenics (U.K.)
- BTG International Inc. (U.S.)
- CryoConcepts LP (U.S.).
- Zimmer MedizinSysteme GmbH (Germany)
- Medtronic (Ireland)
- Cortex Technology (Denmark)
- CooperSurgical, Inc. (U.S.)
- AtriCure, Inc (U.S.)
- Hologic, Inc. (U.S).
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Teva Pharmaceutical Industries Ltd.(Israel)
- AbbVie Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
SKU-